Syntis Bio Launches, Focusing On Oral Obesity Drugs And Rare Diseases

 
• By Jessica Merrill

The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.

intestine
Syntis bio is developing drugs for obesity • Source: Shutterstock

More from Start-Ups & SMEs

More from Business